Melfalan Teva (Melphalan)

Melphalan belongs to the alkylating agent class. It creates covalent bonds between DNA strands, forming cross‑links that block DNA replication and transcription. This interference triggers cell cycle arrest and ultimately leads to apoptosis of rapidly dividing cancer cells.

The dosage of Melfalan Teva is individualized by the prescribing oncologist based on the specific cancer type, disease stage, patient weight, renal function and treatment protocol. Only a qualified healthcare professional can determine the appropriate dose and schedule.

Melphalan is classified as a potent cytotoxic agent and may cause fetal harm. It is generally contraindicated during pregnancy and should not be used by breastfeeding mothers because it can be excreted in milk. Patients should discuss family planning with their physician before starting therapy.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and import documentation.

Melphalan is an alkylating agent, distinct from antimetabolites, taxanes or anthracyclines. Compared with other alkylators, it has a broad spectrum against both solid tumours and hematologic malignancies but shares similar toxicity profiles, such as myelosuppression. Choice of therapy depends on tumour type, prior treatment history and patient tolerance.

Melfalan Teva should be stored at ambient temperature, below 25 °C, in its original packaging. The container should be kept away from moisture, direct sunlight and extreme temperatures to maintain product stability until preparation for intravenous administration.

Melfalan Teva is supplied for intravenous infusion. The drug is reconstituted according to the manufacturer's instructions and administered by a qualified healthcare professional, typically over a set period of time as defined by the treatment protocol.

Serious risks include severe myelosuppression leading to infection or bleeding, pulmonary toxicity such as interstitial pneumonitis, secondary malignancies, renal impairment and cardiac arrhythmias. Patients should be closely monitored for these complications throughout treatment.

Melfalan Teva is contraindicated in patients with known hypersensitivity to melphalan or any component of the formulation, in those receiving live vaccines, and in pregnant or breastfeeding individuals. Caution is also advised for patients with severe renal or hepatic impairment.